DexCom (DXCM) is under the spotlight after several class action lawsuits were filed claiming the company made unauthorized changes to its G6 and G7 glucose monitoring devices. These changes could ...
A trio of stocks made an impressive leap in their Benzinga Edge value scores this week, with one standout making a 138% jump.
A software defect could cause the app to terminate, resulting in missed alerts or alarms. Dexcom required users to download ...
StockStory.org on MSN
The 5 Most Interesting Analyst Questions From DexCom’s Q3 Earnings Call
DexCom's third quarter was met with a negative market reaction despite outpacing Wall Street’s revenue and adjusted EPS ...
Dexcom has issued a Class I recall for its G6 Android app due to crashes that could cause users to miss critical glucose ...
DexCom (NASDAQ:DXCM) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, ...
DexCom treats about 2.5 million patients, with tons of room for more. The company's Q2 guidance bombshell tanked the stock. Competition from an unexpected source raises long-term concerns worth ...
Thinking about buying or holding DexCom stock? You’re not alone. Whether you’re a long-term investor or just looking for a timely healthcare pick, DexCom probably caught your attention for its role in ...
Dexcom has rebounded since my last update, but I maintain a 'Hold' rating due to continued overvaluation and limited upside potential. Growth remains solid, especially in sensors and U.S. expansion, ...
Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.
MADRID--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring (CGM), announced today the Dexcom G6 CGM System has received the CE Mark for use during pregnancy in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback